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Introduction {#s1}
============

Previous studies in patients with idiopathic pulmonary arterial hypertension (IPAH),^[@EHV337C1]^ inoperable chronic thrombo-embolic pulmonary hypertension (CTEPH),^[@EHV337C6]^ associated PAH (APAH) in connective tissue disease,^[@EHV337C7]^ and APAH in congenital heart disease^[@EHV337C8]^ have shown beneficial effects of exercise training as add-on to disease-targeted medical therapy increasing exercise capacity and quality of life (QoL).^[@EHV337C1],[@EHV337C4],[@EHV337C5]^ In four smaller studies, a randomized, controlled trial design has been performed.^[@EHV337C1],[@EHV337C3],[@EHV337C5],[@EHV337C9]^ These trials assessed patients with IPAH and inoperable CTEPH and showed an improvement of 6 min walking distance (6MWD), cardiorespiratory function, fatigue, activity, and QoL parameters by exercise training. In further prospective, uncontrolled trials, similar results have been obtained and long-term follow-up revealed excellent 1- and 2-year survival rates of 95--100% in the patients who had participated in the training programme and continued training at home.^[@EHV337C4],[@EHV337C6],[@EHV337C10]^ The sample size of all these studies was relatively small (19--183 patients). Despite these limitations, the recommendation for this thoroughly supervised rehabilitation including exercise training has been upgraded to Class I, with a Level of Evidence of A within the last world congress in Nice in 2013.^[@EHV337C11],[@EHV337C12]^ This recommendation was combined with the request to perform further randomized controlled multicentre trials.^[@EHV337C12]^ The mechanisms for the improvement of symptoms, exercise, and functional capacity and the possible effects on prognosis are still not completely understood.

The improvement of muscle function such as increase in capillarization and change of fibre type by exercise training^[@EHV337C2]^ has already been shown in PH. There is also evidence that exercise training influences the pulmonary vasculature,^[@EHV337C13]^ with a regulating effect on pulmonary vascular remodelling. The effect of exercise training on peak oxygen consumption (VO~2~/kg) is inconsistent in PH trials. Few uncontrolled trials using exercise training in an outpatient setting did not observe a significant improvement in VO~2~.^[@EHV337C2],[@EHV337C14],[@EHV337C15]^ Up to now, there is no study investigating the effect of exercise training on peak VO~2~/kg as primary endpoint, allowing a confirmative conclusion. Furthermore, there is growing evidence that training may improve right ventricular (RV) function. Animal models suggested a beneficial effect of training on the RV, such as a reduction of RV end-diastolic pressure and increase in RV capillary density (+86%, *P* \< 0.05).^[@EHV337C16],[@EHV337C17]^

The effect of exercise training on cardiopulmonary function and RV haemodynamics is of high interest and needs to be further assessed using cardiopulmonary exercise testing (CPET) and right heart catheterization (RHC) before and after training. Recent publications have shown that peak oxygen uptake (VO~2~), cardiac index (CI),^[@EHV337C18]^ and systolic pulmonary arterial pressure during exercise are important independent predictors for survival.^[@EHV337C19]^

Therefore, the aim of this study was to perform a large, prospective, randomized trial to investigate the impact of exercise training on peak VO~2~ as an important prognostic factor in patients with severe PAH or CTEPH and right heart failure. The study was also aimed to provide first insights into the effects of exercise training on invasively measured haemodynamics.

Methods {#s2}
=======

Study population and design {#s2a}
---------------------------

Patients with PAH and inoperable or persistent CTEPH and chronic right heart failure who were stable on disease-targeted medication for at least 2 months prior to inclusion were randomly assigned to a control and a training group. Medication remained unchanged during the study period. Clinical examinations including RHC were performed at baseline and after 15 weeks. During the study, patients of the control group did not receive any advice on exercise training (*Figure [1](#EHV337F1){ref-type="fig"}*).

![Study design. The flowchart shows the number of allocated patients for each treatment group, the number of patients valid for analysis, and the number and reasons for exclusion, respectively (original data).](ehv33701){#EHV337F1}

All patients gave their written informed consent to the study. The study was approved by the Ethics Committee of the University of Heidelberg, Germany. The study was registered at clinicaltrials.gov (NCT01394367).

Outcome measures {#s2b}
----------------

Primary endpoint was the change in peak VO~2~/kg. Secondary endpoints were the change from baseline to 15 weeks in invasively measured haemodynamics at rest and during symptom-limited exercise, 6MWD, workload QoL questionnaire (SF-36), World Health Organization (WHO) functional class, and N-terminal prohormone brain natriuretic peptide (NT-proBNP). QoL questionnaires were analysed in a blinded fashion. Patients in the control group went on with their usual lifestyle during the study. Efficacy parameters were evaluated at baseline and week 15, as described previously.^[@EHV337C1],[@EHV337C10]^ Assessment of 6MWD, SF-36, and other efficacy parameters were performed by investigators who were blinded to the clinical data. Changes in WHO functional class and Borg dyspnoea scale (with 6 representing no exertion and 20 maximal exertion)^[@EHV337C22]^ were also analysed. CPET was carried out as supine cycle exercise, as described previously.^[@EHV337C1]^ Systolic and diastolic systemic blood pressures, workload, heart rate, ventilation, and VO~2~ were measured breath-by-breath. In patients dependent on long-term oxygen therapy, oxygen supplementation was paused throughout and resupplied directly after termination of the test.

RHC was performed at baseline and 15 weeks. Patients were examined on a variable load supine cycle ergometer (model 8420; KHL Corp., Kirkland, WA, USA). The examination at rest and during symptom-limited exercise was performed in a supine position using the transjugular approach with an 8F introducer set (MXI100, MEDEX, Smiths Group Plc, UK). RHC was performed by triple-lumen 7F-Swan-Ganz thermodilution catheters (Edwards Lifesciences, Irvine, CA, USA). Workload started at 25 W and was increased every 2 min for 25 W until symptom-limited exercise capacity was reached. Cardiac output (CO) was measured at least in triplicate at rest and in duplicate at the end of each workload during exercise by thermodilution with a variation of \<10% between the measured values. The zero reference point for pressure recordings was set at the level of the right atrium in the mid-axillary line (phlebostatic axis). All examinations and measurements were performed by the same experienced team. There were no complications.

Rehabilitation programme with exercise training {#s2c}
-----------------------------------------------

The exercise and respiratory training was performed as described before^[@EHV337C1],[@EHV337C10]^ and was started in-hospital for 3 weeks in the Rehabilitation Clinic Königstuhl in Heidelberg. We performed a programme especially developed for PH patients with at least 1.5 h/day exercise training (in intervals distributed over the day), consisting of interval cycle ergometer training at low workloads at 7 days a week, walking, dumbbell training of single muscle groups using low weights (500--1000 g), and respiratory training at 5 days/week. The training was continued at home with at least 15 min/day at 5 days a week for the following 12 weeks.

Besides physical training, patients received mental training to improve their perception of their individual physical abilities and limits. Psychological support was offered to all participants. The training programme was closely supervised by physical therapists and physicians specialized in rehabilitation medicine and by PH experts, as described before.^[@EHV337C1]^ Adverse events were recorded whenever they occurred. Oxygen saturation and heart rate were monitored continuously throughout the training and were used to adjust the training intensity. When patients\' oxygen saturation fell below 90% during exercise, they received oxygen supply (3--10 L/min) throughout the training. Patients who were on oxygen therapy 16--24 h/day before inclusion into this study remained on oxygen throughout the training programme. At discharge from hospital after 3 weeks, patients received an individualized training manual and ordered a cycle ergometer for use at home.

Statistical methods {#s2d}
-------------------

The analyses were performed by two statisticians (N.E. and C.F.). Data are given as mean values ± standard deviations. For the description of effects, we present changes in absolute values and changes in per cent of the individual baseline value.

Calculation of sample size was based on the primary efficacy endpoint, which was defined as the change in peak VO~2~/kg between baseline and 15 weeks of exercise training. The null hypothesis to be assessed in the confirmatory analysis states that there is no difference in the changes of the peak VO~2~/kg value between the intervention and the control group. To detect a placebo-adjusted difference in peak VO~2~/kg of 2 mL/min/kg, with a standard deviation of 3 mL/min/kg, with a power of 80%, and a two-sided significance level of 5%, it was calculated that 45 patients were required in each treatment arm. Primary efficacy analysis was performed by an analysis of covariance (ANCOVA) model including baseline values as covariate, thereby yielding a power advantage over the standard *t*-test used for sample size calculation.

The secondary endpoints were compared between groups by an ANCOVA including baseline values as covariate. For analysis of categorical data, the McNemar--Bowden test was used.

To include missing values, we performed two sensitivity analyses: (i) multiple imputation analysis based on multiple regression models with 20 imputed data sets and (ii) a responder analysis regarding missing values and worsening of the parameters as non-responder. For the multiple imputation analysis, the combined results are stated. Threshold between response and non-response was set as 0. The responder analysis with number/percentage of responders vs. non-responders was performed by χ^2^ test. All tests were two-sided, and *P*-values less than 0.05 were considered statistically significant. All analyses were carried out with IBM SPSS V20 (IBM Corp. Armonk, NY, USA).

Statement of responsibility {#s2e}
---------------------------

The authors had full access to the data and take full responsibility for its integrity. All authors have read and agree to the manuscript as written.

Results {#s3}
=======

Study population and randomization {#s3a}
----------------------------------

Ninety-five consecutive patients with invasively diagnosed PAH and inoperable or persistent CTEPH under optimized medication therapy were included (*Figure [1](#EHV337F1){ref-type="fig"}*). Eight patients were not eligible for the study: one patient had an alteration in his/her medication, two patients were not able to perform an ergometer test, and five patients had an invalid ergometer test at baseline. Thus, the study group consisted of 87 patients who were randomized into a control and a training group (71% PAH, 29% CTEPH, 79% WHO functional class III, 54% female, 56 ± 15 years) (*Figure [1](#EHV337F1){ref-type="fig"}* and *Table [1](#EHV337TB1){ref-type="table"}*).

###### 

Baseline characteristics

  Baseline characteristics                          Control       Training
  ------------------------------------------------- ------------- -------------
  Patients, *n*                                     41            46
  Gender, male/female                               20/21         20/26
  Age (years)                                       57 ± 15       55 ± 15
  Height (cm)                                       171 ± 8       170 ± 9
  Weight (kg)                                       79 ± 18       75 ± 18
  WHO functional class, no. (%) baseline                          
   II                                               6 (15%)       8 (18.2%)
   III                                              30 (75%)      36 (81.8%)
   IV                                               4 (10%)       0 (0%)
  Diagnosis                                                       
   Pulmonary arterial hypertension                  26 (63.4%)    35 (76.1%)
   CTEPH                                            15 (36.5%)    11 (23.9%)
  NT-proBNP (pg/mL)                                               
   Baseline                                         1114 ± 1386   1163 ± 2520
  Right heart catheterization                                     
   Mean pulmonary arterial pressure (mmHg)          37.6 ± 11.8   41.0 ± 11.7
   Pulmonary vascular resistance (dyn × s /cm^5^)   512 ± 338     540 ± 267
   Central venous pressure (mmHg)                   7.1 ± 4.7     7.5 ± 3.7
   Pulmonary arterial oxygen saturation (%)         64.3 ± 9.4    64.7 ± 9.9
   Pulmonary arterial wedge pressure (mmHg)         9.4 ± 3.8     9.4 ± 3.5
   Cardiac index (L/min/m^2^)                       2.69 ± 0.89   2.68 ± 0.73
  PAH-targeted medication                                         
   Endothelin receptor antagonists                  29 (70.7%)    33 (71.7%)
   Phosphodiesterase-5-inhibitors                   30 (73.2%)    31 (67.4%)
   Prostanoids inhaled                              6 (14.6%)     3 (6.5%)
   Prostanoids per os                               0 (0%)        1 (2.2%)
   Prostanoids intravenous                          0 (0%)        0 (0%)
   Calcium channel blockers                         3 (7.3%)      5 (10.9%)
   Imatinib                                         1 (2.4%)      0 (0%)
   Soluble guanylate cyclase-stimulator             3 (7.3%)      6 (13%)
  Combination therapy                                             
   Monotherapy                                      14 (35%)      13 (33.3%)
   Dual therapy                                     22 (55%)      20 (51.3%)
   Triple therapy                                   4 (10%)       6 (15.4%)
   Oxygen therapy, yes/no                           20/21         17/25

Values are mean ± standard deviation.

For the category WHO functional class, values were missing for one patient in the control group and two patients in the training group. For the category NT-proBNP at baseline, values were missing for 12 patients in the control group. For the categories mean pulmonary arterial pressure and pulmonary vascular resistance, values were missing for seven patients in the control group and six patients in the training group. For the category central venous pressure, values were missing for 10 patients in the control group and 8 in the training group. For the category pulmonary artery oxygen saturation, 20 values were missing for the control group and 16 for the training group. For the category pulmonary arterial wedge pressure, eight values were missing for the control group and six for the training group. For the category cardiac index, seven values were missing for both training and control groups.

The control and training groups did not differ in their baseline characteristics, disease severity, or medication (*Table [1](#EHV337TB1){ref-type="table"}*).

Primary endpoint: change in peak oxygen uptake {#s3b}
----------------------------------------------

Peak VO~2~/kg significantly improved in the training group with +3.1 ± 2.7 mL/min/kg (baseline 13.3 ± 3.6 mL/min/kg; mean increase relative to baseline +24.3%) vs. −0.2 ± 2.3 mL/min/kg (baseline 12.7 ± 4.0 mL/min/kg; mean increase relative to baseline +0.9%) in the control group (*P* \< 0.001; *Figure [2](#EHV337F2){ref-type="fig"}* and *Table [2](#EHV337TB2){ref-type="table"}*). In the training group, 91.7% of the patients reached a peak VO~2~/kg of ≥11.5 mL/min/kg, compared with the control group with 50%.

###### 

Change echocardiography, CPET, and haemodynamics

  Characteristics                                                        Training group   Control group   *P*-value                                                              
  ---------------------------------------------------------------------- ---------------- --------------- ----------------------- ------------- ------------ ------------------- ------------
   Mean 6 min walking distance (m)                                       453 ± 91         29 ± 53         5.5 (1.7, 9.3)          413 ± 95      −12 ± 46     −1.9 (−6, 2.25)     0.002
   Laboratory parameters                                                                                                                                                         
    NT-proBNP (pg/mL)                                                    1163 ± 2520      −89 ± 1387      13.2 (−9, 35)           1114 ± 1386   141 ± 827    39.9 (−21, 101)     0.44
   Cardiopulmonary exercise testing                                                                                                                                              
    Peak VO~2~/kg (mL/min/kg)                                            13.3 ± 3.6       3.1 ± 2.7       24.3 (17.1, 31.4)       12.7 ± 4.0    −0.2 ± 2.3   0.9 (−6.4, 8.3)     \<0.001
    Peak VO~2~ (mL/min)                                                  986 ± 294        233 ± 209       23.2 (16.6, 30)         992 ± 275     −28 ± 150    −2.4 (−7, 2.2)      \<0.001
    Oxygen pulse \[(mL/min)/min^−1^\]                                    8.2 ± 2.4        0.6 ± 1.1       7.4 (3.5, 11.2)         8.0 ± 2.1     0.1 ± 1.1    1.5 (−2.3, 5.3)     0.07
    HR rest (1/min)                                                      74 ± 11          2 ± 10          3.8 (−0.8, 8.4)         80 ± 11       −4 ± 11      −4.8 (−8.8, −0.8)   0.18
    HR max (1/min)                                                       122 ± 21         14 ± 15         12.8 (8, 17.7)          125 ± 17      −4 ± 12      −2.8 (−5.9, 0.2)    \<0.001
    RR sys at rest (mmHg)                                                114 ± 18         −5 ± 17         −3.0 (−7.4, 1.4)        111 ± 15      2 ± 16       2.6 (−2, 7.2)       0.19
    RR dia at rest (mmHg)                                                72 ± 10          −2 ± 11         −1.1 (−5.6, 3.4)        74 ± 10       −2 ± 11      −1.3 (−6.1, 3.6)    0.78
    RR sys max (mmHg)                                                    140 ± 22         13 ± 24         10.7 (4.3, 17.1)        146 ± 25      −3 ± 23      −0.2 (−5, 4.6)      0.008
    RR dia max (mmHg)                                                    82 ± 12          3 ± 14          6.0 (−0.8, 12.7)        79 ± 13       2 ± 11       3.6 (−0.8, 8.0)     0.34
    Workload max (W)                                                     74 ± 27          18 ± 28         32.1 (15.8, 48.4)       72 ± 23       −1 ± 14      1.8 (−6.4, 10.1)    \<0.001
   Secondary analysis set (*n* = 59: 31 training vs. 28 control)                                                                                                                 
   RHC at rest                                                                                                                                                                   
    mPAP (mmHg)                                                          41 ± 12          −4 ± 10         −7.3 (−13.2, −1.5)      38 ± 12       5 ± 8        16.1 (6.4, 25.8)    0.007
    Cardiac output (L/min)                                               5.0 ± 1.4        0.7 ± 0.9       12.5 (6.3, 18.6)        5.1 ± 1.8     −0.5 ± 1.3   −5.3 (−11.7, 1.1)   \<0.001
    Cardiac index (L/min/m^2^)                                           2.7 ± 0.7        0.2 ± 0.6       9.3 (2.4, 16.2)         2.7 ± 0.9     −0.3 ± 0.8   −6.5 (−13, 0.2)     \<0.001^a^
    PAWP (mmHg)                                                          9 ± 4            2 ± 4           24.4 (9.2, 39.7)        9 ± 4         −0.3 ± 4.7   9.2 (−12, 30)       0.18
    PVR (dyn × s/cm)                                                     540 ± 267        −87 ± 151       −19.3 (−28.4, --10.3)   512 ± 338     87 ± 168     34.5 (1, 68)        \<0.001^a^
   RHC during exercise (exercise *n* = 49: 28 training vs. 21 control)                                                                                                           
    mPAP (mmHg)                                                          66 ± 19          2 ± 10          5.3 (−0.2, 10.8)        58 ± 18       4 ± 9        9.6 (0.7, 18.6)     0.71
    Cardiac output (L/min)                                               10.3 ± 3.4       2.1 ± 2.7       20.4 (11.5, 29.2)       9.1 ± 2.3     −0.3 ± 1.2   −2.0 (−9, 5)        0.002
    Cardiac index (L/min/m^2^)                                           5.4 ± 1.6        1.0 ± 1.4       19.5 (10.4, 28.5)       4.7 ± 1.1     −0.2 ± 0.6   −4.3 (−12, 3)       0.002
    PAWP (mmHg)                                                          15 ± 5           0.6 ± 6         9.7 (−7.5, 26.9)        15 ± 7        0.5 ± 4      7.1 (−4, 19)        0.93
    PVR (dyn × s/cm^5^)                                                  453 ± 219        −44 ± 150       −10.6 (−22.3, 1.1)      439 ± 272     26 ± 175     15.1 (−6, 37)       0.16

Values are mean ± standard deviation; two-sided *P*-values of ANCOVA are given.

NT-proBNP, N-terminal pro-B-type natriuretic peptide; PAP, pulmonary arterial pressure; sys, systolic; dia, diastolic; m, mean; HR, heart rate; RR, blood pressure; TAPSE, tricuspid annular plane systolic excursion; RHC, right heart catheter; PAWP, pulmonary arterial wedge pressure; PVR, pulmonary vascular resistance.

^a^No significant difference in multiple imputation analysis. Frequency of missing values within the analysis sets within groups was always below 15%.

![Primary endpoint: change in peak oxygen uptake. Left graph: The abscissa shows peak VO~2~/kg at baseline, and the ordinate shows change of peak VO~2~/kg from baseline after 15 weeks for each patient. The solid points represent patients of the training group, and the circles represent patients of the control group. This graph shows equal distribution of baseline peak VO~2~ in both groups as well as changes after 15 weeks of exercise training. Change in peak VO~2~ did not correlate with baseline peak VO~2~. Right graph: the boxplots at the right side show median change of VO~2~ max in the control vs. training group after 15 weeks. A significant increase can be shown in the training group (*P* \< 0.001), whereas the control group shows a small reduction in peak VO~2~ after 15 weeks. Multiple imputations showed the same *P*-value.](ehv33702){#EHV337F2}

Secondary endpoints {#s3c}
-------------------

### Haemodynamics and right heart function {#s3c1}

RHC was performed at baseline and after 17 ± 7.5 weeks in 74 of 87 (81.6%) patients: 34 patients of the training group and 40 patients of the control group agreed to invasive assessment of haemodynamics by RHC. Haemodynamics at rest and during exercise significantly improved in the training group, compared with the control group (*Figure [3](#EHV337F3){ref-type="fig"}*). The measurements at rest (*Figure [3](#EHV337F3){ref-type="fig"}*) revealed a significant improvement of CI (training +0.2 ± 0.6 L/min/m^2^; +9.3% vs. control −0.3 ± 0.9 L/min/m^2^; −6.5%, *P* \< 0.001), CO (training +0.7 ± 0.9 L/min/m^2^; +12.5% vs. control −0.5 ± 1.3 L/min/m^2^; −5.3%, *P* \< 0.001), mean pulmonary arterial pressure (mPAP) at rest (training −4 ± 10 mmHg; −7.3% vs. control +4 ± 8 mmHg; +16.1%, *P* = 0.007), and pulmonary vascular resistance (training −87 ± 151 mmHg; −19.3% vs. control +87 ± 168 mmHg; +34.5%, *P* \< 0.001) in the training group, compared with the control group and baseline. *P*-values for multiple imputations are shown in *Figure [3](#EHV337F3){ref-type="fig"}*.

![Secondary endpoints: haemodynamic function. Results from RHC for mean pulmonary arterial pressure (*A*), pulmonary vascular resistance (*B*), cardiac output (*C*) and cardiac index (*D*) at rest. The graphs depict the change of each parameter in per cent from baseline to 15 weeks after exercise training/no training. The mean changes of the training group, compared with baseline and control, as absolute values are given at the top of each graph with corresponding *P*-values of the ANCOVA for original data and multiple imputations. The bars are representing two times standard error.](ehv33703){#EHV337F3}

Measurements during exercise baseline vs. 15 weeks revealed a significant improvement of CI during exercise (training +1.0 ± 1.4 L/min/m^2^; +19.5% vs. control −0.2 ± 0.6 L/min/m^2^; −4.3%, *P* = 0.002; *Figure [4](#EHV337F4){ref-type="fig"}*) and further haemodynamic parameters in the training group, compared with the control group (*Figure [3](#EHV337F3){ref-type="fig"}* and *Table [2](#EHV337TB2){ref-type="table"}*). Both time points were also analysed for the same workload, which corresponds either to the maximum of baseline or follow-up examination. The analysis at the same workload showed the same results with significant improvement of both CI and CO during exercise (difference from baseline: CO training +1.41 ± 2.13 L/min vs. control −0.38 ± 0.29 L/min, CI training +0.66 ± 1.06 L/min/m^2^ vs. control −0.23 ± 0.66 L/min/m^2^, both *P* = 0.001 for original data; for multiple imputation: both *P* = 0.03 compared with baseline and control).

![Haemodynamics during exercise. The distribution of absolute changes in CI during exercise (*P* \< 0.001) is shown by a boxplot for each group. The training group improved CI by 19.5%, whereas the control group had a decrease of 4.3%. *P*-values are given for the ANCOVA for original data and multiple imputations.](ehv33704){#EHV337F4}

### Further clinical parameters {#s3c2}

After 15 weeks of treatment, the 6MWD and change in the workload during CPET significantly improved in the training compared with the control group (control group corrected change: 6MWD +41 m, *P* = 0.001 and CPET +19 W, *P* \< 0.001; *Figure [5](#EHV337F5){ref-type="fig"}* and *Table [2](#EHV337TB2){ref-type="table"}*).

![6MWD. The figure shows the absolute changes in 6MWD for each patient: patients of the training group as solid lines and patients of the control group as dashed lines. Mean changes are given with darker lines, and error bars indicate ±1 standard error of the mean. Exercise training significantly improved 6MWD compared with baseline (*P* = 0.002). *P*-values are given for the ANCOVA for original data and multiple imputations.](ehv33705){#EHV337F5}

At baseline, all patients had significantly compromised QoL scores compared with the general population. Only for the subscale vitality, *P*-values were significant for both original data and multiple imputation (for original data *P* = 0.036 and for multiple imputation *P* = 0.042) (*Figure [6](#EHV337F6){ref-type="fig"}*).

![QoL. Mean changes of QoL ± 2 standard errors of the mean and sample sizes below each bar. The bars of the control group are shown on the left side of each category. Exercise and respiratory training significantly improved the subscale score for vitality (*P* = 0.036), compared with the control group, in which this parameter slightly worsened. The subscales role limitations due to physical restrictions (*P* = 0.099), role limitations due to emotional restrictions (*P* = 0.09), and general health perception (0.091) were significant in trend in the original data, but showed inconsistent findings in multiple imputation.](ehv33706){#EHV337F6}

For evaluation of WHO functional class, the prepared sheets were not filled in by the investigators for \>50% of the patients, so this parameter was not analysed. NT-proBNP values varied largely within the population at baseline also due to comorbidities such as renal insufficiency and did not show a statistically significant difference between groups (training 979 ± 2811 vs. control 1074 ± 1424; *P* = 0.44). Echocardiography data showed no statistically significant change in right heart areas and systolic pulmonary arterial pressure between groups. Tricuspid annular plane systolic excursion significantly decreased in the training group compared with the control group.

Sensitivity analysis: responder vs. non-responder {#s3d}
-------------------------------------------------

A sensitivity analysis was performed for primary and secondary endpoints treating missing values as non-responders. Change in workload (training 54% vs. control 21% responders, *P* = 0.002), peak VO~2~ (training 74% vs. control 44%, *P* = 0.006), mPAP (training 64% vs. control 28%, *P* = 0.001), CO (training 59% vs. control 23%, *P* = 0.001), CI (training 51% vs. control 21%, *P* = 0.005), PVR (training 64% vs. control 26%, *P* = 0.001), CO during exercise (training 59% vs. control 21%, *P* = 0.001), and CI during exercise (training 56% vs. control 23%, *P* = 0.003) remained statistically significant.

Discussion {#s4}
==========

This large prospective, randomized, controlled trial evaluates the effect of exercise training on peak VO~2~/kg as primary endpoint and invasively measured haemodynamics in patients with severe PAH and inoperable or persistent CTEPH. To the best of our knowledge, there is only one previous publication performing RHC after training in 20 patients with left heart failure.^[@EHV337C23]^ The results of the study showed an improvement of peak VO~2~/kg, CI, and CO during exercise, suggesting that this treatment might improve RV function. Other prognostic parameters such as CI at rest, pulmonary vascular resistance, mPAP, 6MWD, QoL parameters, and exercise capacity significantly improved in the training group. Bearing in mind that these effects were reached as add-on in patients with optimized medical treatment, low-dose exercise training was very effective.

Effect on peak oxygen uptake and RV function {#s4a}
--------------------------------------------

The results of this study confirm previous findings that exercise training improves peak VO~2~/kg in patients with severe PH by approximately 15--25%.^[@EHV337C1],[@EHV337C4],[@EHV337C7],[@EHV337C8],[@EHV337C10]^ Study results that did not show positive effects of exercise training on peak VO~2~/kg^[@EHV337C2],[@EHV337C14],[@EHV337C15]^ may be evoked by less intensive training due to an outpatient setting and by a lower training frequency of three times a week or less. Peak VO~2~ is linearly associated with RV function.^[@EHV337C24],[@EHV337C25]^ Both were severely reduced in our patients at rest and during exercise. RV dysfunction is a crucial factor contributing to functional impairment and mortality. Improvement of peak VO~2~/kg is possibly due to improvement of capillary density of the skeletal muscle, which has been identified before in patients with IPAH.^[@EHV337C2]^

CI and CO significantly improved at rest, during maximal exercise, and when comparing the baseline and follow-up assessments at the same workload. The improvements in haemodynamics at rest and during exercise point out that training may also be beneficial for the RV function, which is a strong prognostic predictor in these patients.^[@EHV337C19],[@EHV337C20],[@EHV337C26],[@EHV337C27]^ CI during exercise has recently been detected to be the most important independent haemodynamic predictor of survival in PH in the investigated cohort,^[@EHV337C18],[@EHV337C20]^ correlated well with the clinical data, and was even more informative than haemodynamics at rest.

Mechanism of exercise training in athletes and patients with left heart failure {#s4b}
-------------------------------------------------------------------------------

Previous studies in healthy athletes have shown that endurance exercise training causes a significant increase in skeletal muscle capillarization, characterized by an elevated capillary density and capillary-to-fibre ratio.^[@EHV337C28]^ The physiological adaptation contributes to enhanced aerobic capacity by increased transport, conductance, and extraction of oxygen in skeletal muscles. In patients with left heart failure, exercise training has shown to improve ventilatory efficiency,^[@EHV337C31]^ the reversal of skeletal muscle atrophy,^[@EHV337C32]^ the attenuation of endothelial dysfunction,^[@EHV337C33]^ and inflammatory mediators.^[@EHV337C34]^ Besides these 'peripheral effects' on skeletal muscle function, it is not known yet whether there is a direct effect of exercise training on the heart muscles. Erbs *et al*.^[@EHV337C37]^ showed improvement of left ventricular ejection fraction, stroke volume, and CO at peak exercise after 12 weeks of exercise training in patients with advanced chronic left heart failure.^[@EHV337C24]^ Wisloff *et al*.^[@EHV337C38]^ reported that after 12 weeks of aerobic-moderate continuous training and aerobic-intense interval training, left ventricular ejection fraction of cardiac patients increased. This study confirmed the effects of exercise training by invasive measurements of pulmonary circulation in patients with PAH/CTEPH and right heart failure.

Limitations {#s4c}
-----------

RHC was an optional assessment in this study. Thus, a referral bias may have occurred as only 83% of the patients received RHC. The haemodynamic effects of this study may therefore serve as first results to plan prospective, randomized studies on the effects of exercise training on haemodynamics at rest and during exercise. The training group showed a significant increase in heart rate during exercise when compared with the control group. This may be a hint for a higher volitional effort. However, haemodynamics also showed a significant improvement when examinations were compared for the same workload.

In a randomized controlled trial, a responder analysis does not reflect a worst-case scenario and is therefore not appropriate as a mere sensitivity analysis. The findings of both responder analysis and multiple imputations, however, showed almost the same significant parameters as the original data analysis.

NT-proBNP values, which are associated with disease progression, showed no statistical difference between changes of control and training groups. This may also be influenced by the large variation of values, as in six patients NT-proBNP was highly increased due to renal insufficiency.

It is a general issue of exercise training studies that they cannot be performed in a blinded fashion and that a referral bias towards highly motivated patients with a better outcome may occur.

Conclusion {#s5}
==========

This prospective, randomized, controlled trial confirms that low-dose exercise training at 4--7 days/week as add-on to PAH-targeted medication significantly improves peak VO~2~. The study indicates that exercise training improves cardiopulmonary parameters such as pulmonary vascular resistance and CI at rest and during exercise, leading to an increase in exercise capacity and QoL. The results of the study suggest that this therapy can improve RV function and other important prognostic parameters. The precise mechanism through which exercise-based interventions benefit PH patients still remains unclear. Further, larger multicentre trials using CI during exercise and time to clinical worsening as primary endpoints are necessary to confirm these results and to assess the impact of this therapy on patient outcomes.
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